🔗 Share this article

Given that the US undertakes sweeping changes to its vaccine recommendations, one figure has emerged somewhat surprisingly: Høeg, a US-based sports physician and epidemiologist who rose to prominence by questioning Covid vaccinations throughout the global health crisis and has concentrated on potential deaths after COVID-19 vaccination in her brief position at the Food and Drug Administration.

Proposed Shifts to Childhood Immunization Program

Agency leaders had intended to announce radical changes to the pediatric vaccination calendar in December, bringing the US with Denmark’s national calendar, according to reports – a substantial departure that would place the US out of step with a large portion of the global community with no evidence for benefit. The announcement has been pushed back until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to speak at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to lead the office this year.

A New Direction at the Agency

The acting appointment could signify a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Høeg has repeatedly called for halting specific pediatric vaccine recommendations in the US in order to be more like Denmark's approach, a nation with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

To date statements, she has persisted in emphasizing on vaccines – typically the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Questions Over Background

Høeg has no apparent experience in drug development, approval processes or administrative roles, which has been standard for former leaders of the CBER. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in leading a sizeable institution. She lacks background in drug approvals.”

Previous heads of CBER would “understand regulatory frameworks and the underlying principles of drug development”, said Janet Woodcock. “Objectively, she lacks the sort of resume that prior appointees who headed the center have had.”

CDER has an immense workload at the FDA, Woodcock stated.

“Many people just focuses on the novel medication approvals, but the generic program clears a multitude of generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and all of those must be managed,” she explained. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a major leadership component to the role, which supervises in excess of 5,000 staff members. “It is a enormous leadership role, if you perform it correctly,” the former official said.

Agency Reaction and Disputed Programs

When asked about questions about Høeg’s qualifications and whether this assignment signifies more teamwork among agency officials on vaccines, a representative stated that the “inquiries rely on incorrect premises”.

“This background aligns with the duties of her job,” the spokesperson said, pointing to the time Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s controversial priority voucher program, a controversial one-day medication authorization process that allegedly troubled her former heads. “By what process are these therapies being picked for this voucher program? Who takes the decisions?” Dr. Howard said. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA seems to be moving towards laxer rules of all drugs, except for immunizations.”

Established Track Record on Vaccines

With vaccines, Dr. Høeg has a clearer, if problematic, track record, critics have noted. She authored a analysis using non-validated crowd-sourced reports to estimate the incidence of myocarditis following Covid vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the incoming administration encompassed revising rules for novel immunizations and halting “optional” immunizations, she stated following the vote on a online show. At the agency, Dr. Høeg has allegedly suggested excluding young men from getting COVID-19 vaccines.

“She is an complete true believer who commences with her conclusions and reverse-engineers to fit the data in a very disingenuous, dishonest way,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow skeptics, {like|